PuraPharm (01498) Schedules 25 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend
Bulletin Express
Mar 13
PuraPharm Corporation Limited (01498) has announced that its board of directors will convene on 25 March 2026. The meeting’s agenda includes:
• Approval of the audited annual results for the financial year ended 31 December 2025.
• Authorisation for the publication of the FY2025 results announcement.
• Deliberation on the declaration of a potential final dividend.
The board currently comprises three executive directors—Chairman and Executive Director Chan Yu Ling, Abraham; Man Yee Wai, Viola; and Dr. Tsoi Kam Biu, Alvin—alongside two non-executive directors and three independent non-executive directors.
The company will release further details, including the FY2025 financial figures and any dividend decision, following board approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.